Overview

Darapladib China PK

Status:
Completed

Trial end date:
2014-01-04

Target enrollment:

Participant gender:

Summary

This study is to evaluate pharmacokinetics (PK), pharmacodynamics (PD) and safety of 160 mg enteric-coated micronised free base darapladib in healthy Chinese subjects.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Darapladib